Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.

Source:http://linkedlifedata.com/resource/pubmed/id/18323557

J. Clin. Oncol. 2008 Mar 10 26 8 1324-30

Download in:

View as

General Info

PMID
18323557